Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Residues 1680-1684 in the A3 Domain of Factor VIII Contain a Novel Thrombin-Interactive Site Responsible for Proteolytic Cleavage at Arg 1689

Yuto Nakajima, MD, Keiji Nogami, MD PhD, Hiroaki Minami, MD, Kana Sasai, Midori Shima, MD PhD

Blood (2019) 134 (Supplement_1): 1107.

https://doi.org/10.1182/blood-2019-129313

Published: 2019

Journal Articles

Pre-Analysis for Hemostatic Effect of Bypassing Agents in Hemophilia a Patients with Inhibitors Under the Emicizumab Prophylaxis By Global Assays

Shoko Furukawa, MD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Ryu Kasai, MSc, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 3793.

https://doi.org/10.1182/blood-2018-99-114355

Published: 2018

Journal Articles

Coagulation and Fibrinolysis Imbalance Demonstrated By Novel Simultaneous Thrombin and Plasmin Generation Assay during L-Asparaginase Treatment Phase of Induction Therapy in Pediatric Acute Lymphoblastic Leukemia

Takashi Ishihara, MD, Keiji Nogami, MD PhD, Satoshi Ochi, MD, Toshiaki Ishida, MD PhD, Yoshiyuki Kosaka, MD PhD, Akihisa Sawada, MD PhD, Masami Inoue, MD, Shinya Osone, MD PhD, Toshihiko Imamura, MD PhD, Hajime Hosoi, MD PhD, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 3972.

https://doi.org/10.1182/blood-2018-99-110411

Published: 2018

Journal Articles

Assessment of Emicizumab-Driven Clot Stability in Hemophilia a Model

Kenichi Ogiwara, MD PhD, Hiroki Horiuchi, Keiji Nogami, MD PhD, Takehisa Kitazawa, DVM, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 2478.

https://doi.org/10.1182/blood-2018-99-118379

Published: 2018

Journal Articles

A Novel Hemostatic Monitoring System Convertible to FVIII Activity Based on Non-Activated ROTEM (NATEM) for Hemophilia a Patients during Emicizumab Prophylaxis

Koji Yada, MD PhD, Keiji Nogami, MD PhD, Ryu Kasai, MSc, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 3782.

https://doi.org/10.1182/blood-2018-99-117877

Published: 2018

Journal Articles

Activated FVIII Released from FVIII/VWF Complex Facilitates Thrombus Development Under High Shear Flow Condition

Hiroaki Yaoi, MD, Yasuaki Shida, MD PhD, Takehisa Kitazawa, Kunihiro Hattori, PhD, Midori Shima, MD PhD, Keiji Nogami, MD PhD

Blood (2016) 128 (22): 83.

https://doi.org/10.1182/blood.V128.22.83.83

Published: 2016

Journal Articles

A Novel Clot Waveform Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-Fixa/Fx Bispecific Antibody, Emicizumab

Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Yuka Tabuchi, Tetsuhiro Soeda, PhD, Nobuo Arai, Takehisa Kitazawa, Hidenari Takaoka, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2016) 128 (22): 1388.

https://doi.org/10.1182/blood.V128.22.1388.1388

Published: 2016

Journal Articles

Mechanism of Tissue Factor (TF) Enhancing Factor (F)VIII Activity on FXa Generation in Initial Phase of Coagulation and Interaction Between TF and FVIII C2 Domain

Furukawa Shoko, Keiji Nogami, MD PhD, Kenichi Ogiwara, MD PhD, Midori Shima, MD PhD

Blood (2016) 128 (22): 1391.

https://doi.org/10.1182/blood.V128.22.1391.1391

Published: 2016

Journal Articles

A New Classification of Mild/Moderate Hemophilia Α Based on a Multi-Dimensional FVIII(a) Functions Evaluated By a Plasma-Based Factor Xa Generation

Koji Yada, MD PhD, Keiji Nogami, MD PhD, Arisa Takenaka, Takeshi Kawamura, Midori Shima, MD PhD

Blood (2016) 128 (22): 1392.

https://doi.org/10.1182/blood.V128.22.1392.1392

Published: 2016

Journal Articles

Shift to Anti-Fibrinolysis on the Administration of L-Asparaginase (L-Asp) during Induction Therapy for Pediatric Acute Lymphoblastic Leukemia (ALL)

Takashi Ishihara, MD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Yasufumi Takeshita, MD, Akitaka Nomura, MD, Satoshi Ochi, MD, Toshiaki Ishida, MD PhD, Yoshiyuki Kosaka, MD PhD, Akihisa Sawada, PhD MD, Masami Inoue, MD, Midori Shima, MD PhD

Blood (2016) 128 (22): 5156.

https://doi.org/10.1182/blood.V128.22.5156.5156

Published: 2016

Journal Articles

Identification of a Factor X-Interactive Site on the Factor VIII A2 Domain

Masahiro Takeyama, MD PhD, Keiji Nogami, MD PhD, Shoko Furukawa, MD, Midori Shima, MD PhD

Blood (2016) 128 (22): 3760.

https://doi.org/10.1182/blood.V128.22.3760.3760

Published: 2016

Journal Articles

Identification of a Protein S-Interactive Site on the Factor VIII C2 Domain

Furukawa Shoko, Masahiro Takeyama, MD PhD, Midori Shima, MD PhD, Keiji Nogami, MD PhD

Blood (2016) 128 (22): 3763.

https://doi.org/10.1182/blood.V128.22.3763.3763

Published: 2016

Journal Articles

The Acidic Region of Factor VIII Light Chain Contains the Thrombin-Binding Site(s) Responsible for the Cleavage at Arg 1689

Hiroaki Minami, MD, Keiji Nogami, MD PhD, Midori Shima, MD PhD

Blood (2015) 126 (23): 2270.

https://doi.org/10.1182/blood.V126.23.2270.2270

Published: 2015

Journal Articles

Enhanced Global Hemostatic Potentials with a Bispecific Antibody to Factors IXa and X (ACE910) in the Whole Blood By Rotation Thromboelastometry (ROTEM)

Koji Yada, MDPhD, Keiji Nogami, MD PhD, Yasuaki Shida, MD PhD, Masahiro Takeyama, MD PhD, Ryu Kasai, MSc, Midori Shima, MD PhD

Blood (2015) 126 (23): 3503.

https://doi.org/10.1182/blood.V126.23.3503.3503

Published: 2015

Journal Articles

Anti-Factor IXa/Factor X Antibody (ACE910) Improves the Coagulation Function in Acquired Hemophilia A ex vivo

Masahiro Takeyama, MD PhD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2015) 126 (23): 3565.

https://doi.org/10.1182/blood.V126.23.3565.3565

Published: 2015

Journal Articles

Outcome of the Japanese Immune Tolerance Induction (ITI) Registry and Predictors of Successful ITI

Keiji Nogami, MD PhD, Masashi Taki, MD PhD, Tadashi Matsushita, MD PhD, Shouichi Ohga, MD PhD, Hideji Hanabusa, Toshiaki Oka, MD, Yasuo Horikoshi, MD, Kagehiro Amano, MD PhD, Midori Shima, MD PhD

Blood (2015) 126 (23): 3526.

https://doi.org/10.1182/blood.V126.23.3526.3526

Published: 2015

Journal Articles

ACE910 Facilitates Its Hemostatic Effect with the Lower Concentration of Factor X Than That Required for Factor VIIa-Driven Coagulation

Koji Yada, MD PhD, Keiji Nogami, MD PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2015) 126 (23): 1077.

https://doi.org/10.1182/blood.V126.23.1077.1077

Published: 2015

Journal Articles

Safety and Prophylactic Efficacy Profiles of ACE910, a Humanized Bispecific Antibody Mimicking the FVIII Cofactor Function, in Japanese Hemophilia A Patients Both without and with FVIII Inhibitors: First-in-Patient Phase 1 Study

Midori Shima, MD PhD, Hideji Hanabusa, MD, Masashi Taki, MDPhD, Tadashi Matsushita, MD PhD, Tetsuji Sato, MD, Katsuyuki Fukutake, MD PhD, Naoki Fukazawa, Shingo Maisawa, Koichiro Yoneyama, Keiji Nogami, MD PhD

Blood (2014) 124 (21): 691.

https://doi.org/10.1182/blood.V124.21.691.691

Published: 2014

Journal Articles

Activated Protein C-Catalyzed Factor Va Inactivation Predominantly Contributes to the Downregulation of Coagulation Rather Than Factor VIIIa Inactivation

Koji Yada, MD PhD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2014) 124 (21): 4222.

https://doi.org/10.1182/blood.V124.21.4222.4222

Published: 2014

Journal Articles

The Hemostatic Impairment in Mild Hemophilia Α Possessing Arg593Cys Mutation Is Caused By the Attenuated Binding to Phospholipid

Nao Kamiya, Koji Yada, MD PhD, Midori Shima, MD PhD, Keiji Nogami, MD PhD

Blood (2014) 124 (21): 2810.

https://doi.org/10.1182/blood.V124.21.2810.2810

Published: 2014

NARROW

Residues 1680-1684 in the A3 Domain of Factor VIII Contain a Novel Thrombin-Interactive Site Responsible for Proteolytic Cleavage at Arg 1689

Pre-Analysis for Hemostatic Effect of Bypassing Agents in Hemophilia a Patients with Inhibitors Under the Emicizumab Prophylaxis By Global Assays

Coagulation and Fibrinolysis Imbalance Demonstrated By Novel Simultaneous Thrombin and Plasmin Generation Assay during L-Asparaginase Treatment Phase of Induction Therapy in Pediatric Acute Lymphoblastic Leukemia

Assessment of Emicizumab-Driven Clot Stability in Hemophilia a Model

A Novel Hemostatic Monitoring System Convertible to FVIII Activity Based on Non-Activated ROTEM (NATEM) for Hemophilia a Patients during Emicizumab Prophylaxis

Activated FVIII Released from FVIII/VWF Complex Facilitates Thrombus Development Under High Shear Flow Condition

A Novel Clot Waveform Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-Fixa/Fx Bispecific Antibody, Emicizumab

Mechanism of Tissue Factor (TF) Enhancing Factor (F)VIII Activity on FXa Generation in Initial Phase of Coagulation and Interaction Between TF and FVIII C2 Domain

A New Classification of Mild/Moderate Hemophilia Α Based on a Multi-Dimensional FVIII(a) Functions Evaluated By a Plasma-Based Factor Xa Generation

Shift to Anti-Fibrinolysis on the Administration of L-Asparaginase (L-Asp) during Induction Therapy for Pediatric Acute Lymphoblastic Leukemia (ALL)

Identification of a Factor X-Interactive Site on the Factor VIII A2 Domain

Identification of a Protein S-Interactive Site on the Factor VIII C2 Domain

The Acidic Region of Factor VIII Light Chain Contains the Thrombin-Binding Site(s) Responsible for the Cleavage at Arg 1689

Enhanced Global Hemostatic Potentials with a Bispecific Antibody to Factors IXa and X (ACE910) in the Whole Blood By Rotation Thromboelastometry (ROTEM)

Anti-Factor IXa/Factor X Antibody (ACE910) Improves the Coagulation Function in Acquired Hemophilia A ex vivo

Outcome of the Japanese Immune Tolerance Induction (ITI) Registry and Predictors of Successful ITI

ACE910 Facilitates Its Hemostatic Effect with the Lower Concentration of Factor X Than That Required for Factor VIIa-Driven Coagulation

Safety and Prophylactic Efficacy Profiles of ACE910, a Humanized Bispecific Antibody Mimicking the FVIII Cofactor Function, in Japanese Hemophilia A Patients Both without and with FVIII Inhibitors: First-in-Patient Phase 1 Study

Activated Protein C-Catalyzed Factor Va Inactivation Predominantly Contributes to the Downregulation of Coagulation Rather Than Factor VIIIa Inactivation

The Hemostatic Impairment in Mild Hemophilia Α Possessing Arg593Cys Mutation Is Caused By the Attenuated Binding to Phospholipid

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only